Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn’s disease

BACKGROUND: Low anti-tumor necrosis factor α (TNFα) serum concentrations may result in lack of treatment response in patients with inflammatory bowel disease. We determined the anti-TNFα drug concentrations in patients with inflammatory bowel disease and investigated whether or not subtherapeutic dr...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Therap Adv Gastroenterol
Autori principali: Carlsen, Arne, Omdal, Roald, Leitao, Kristian Øgreid, Isaksen, Kjetil, Hetta, Anne Kristine, Karlsen, Lars Normann, Aabakken, Lars, Bolstad, Nils, Warren, David, Lundin, Knut E.A., Grimstad, Tore
Natura: Artigo
Lingua:Inglês
Pubblicazione: SAGE Publications 2018
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5881967/
https://ncbi.nlm.nih.gov/pubmed/29623105
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756284818759930
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi